Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large b-cell lymphoma: The emerging standard of care

Oncologist

Volumn 17, Issue 2, 2012, Pages 239-249

  Vassilakopoulos, Theodoros P ^a   Pangalis, Gerassimos A ^b   Katsigiannis, Andreas ^a   Papageorgiou, Sotirios G ^a   Constantinou, Nikos ^c   Terpos, Evangelos ^a   Zorbala, Alexandra ^d   Vrakidou, Effimia ^e   Repoussis, Panagiotis ^f   Poziopoulos, Christos ^g   Galani, Zacharoula ^a   Dimopoulou, Maria N ^a   Kokoris, Stella I ^a   Sachanas, Sotirios ^b   Kalpadakis, Christina ^a   Dimitriadou, Evagelia M ^a   Siakantaris, Marina P ^a   Kyrtsonis, Marie Christine ^a   Dervenoulas, John ^a   Dimopoulos, Meletios A ^a   Meletis, John ^a   Roussou, Paraskevi ^a   Panayiotidis, Panayiotis ^a   Beris, Photis ^a   Angelopoulou, Maria K ^a   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b ATHENS MEDICAL CENTER   (Greece)

^c THEAGENIO CANCER HOSPITAL   (Greece)

^d LAIKO GENERAL HOSPITAL   (Greece)

^e HYGEIA HOSPITAL   (Greece)

^f Peripheral General Anticancer Hospital Metaxa   (Greece)

^g 401 Army Hospital   (Greece)

Author keywords

Chop; Large b cell lymphoma; Primary mediastinal; Radiotherapy; Rituximab; Standard of care

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDNISOLONE; VINCRISTINE;

EID: 84857386754     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0275     Document Type: Article

References (49)

1. Harris NL, Jaffe ES, Stein H et al. Arevised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
2. Banks PM, Warnke RA. Mediastinal (thymic) large B-cell lymphoma. In: Jaffe ES, Harris NL, SteinHet al., eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001;175-176.
3. Savage KJ. Primary mediastinal large B-cell lymphoma. The Oncologist 2006;11:488-495.
4. Lazzarino M, Orlandi E, Pauli M et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: A multicenter study of 106 patients. J Clin Oncol 1997;15: 1646-1653.
5. Todeschini G, Ambrosetti A, Meneghini V et al. Mediastinal large-B-cell lymphoma with sclerosis: A clinical study of 21 patients. J Clin Oncol 1990;8:804-808.
6. Zinzani PL, Martelli M, Bertini M et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients. Haematologica 2002;87:1258-1264.
7. Savage KJ, Al-Rajhi N, Voss N et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: The British Columbia experience. Ann Oncol 2006;17:123-130.
8. Hamlin PA, Portlock CS, Straus DJ et al. Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005;130: 691-699.
9. Zinzani PL, Martelli M, Bendandi M et al. Primary mediastinal large B-cell lymphoma with sclerosis: A clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica 2001;86:187-191.
10. Todeschini G, Secchi S, Morra E et al. Primary mediastinal large B-cell lymphoma (PMLBCL): Long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90:372-376.
11. Seidemann K, Tiemann M, Lauterbach I et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: Treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster group. J Clin Oncol 2003;21:1782-1789.
12. Siracusano L, Balzarotti M, Magagnoli M et al. Primary mediastinal B-cell lymphoma with sclerosis: Report of 11 cases treated with intensified-CHOP plus radiotherapy. Am J Hematol 2005; 78:312-313.
13. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-242.
14. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033.
15. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24: 3121-3127.
16. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116.
17. Pfreundschuh M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
18. Vassilakopoulos TP, Pangalis GA, Anastasopoulou A et al. Rituximab-CHOP (R-CHOP) in the treatment of 441 diffuse large B-cell lymphoma patients: Outcome and prognostic factors focusing to the Revised International Prognostic Index (R-IPI). Haematologica 2009;94(suppl 2):163.
19. Schmitz N, Nickelsen M, Ziepert M et al. Aggressive chemotherapy (CHOEP-14) and rituximab or HDT (MegaCHOEP) and rituximab for young, high-risk patients with aggressive B-cell lymphoma: Results of the MegaCHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;114:abstract 404.
20. Recher C, Coiffier B, Haioun C et al. A prospective randomized study comparing dose intensive immunochemotherapy with R-ACVBP vs standard R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL). Groupe d' Etude des Lymphomes de l'Adulte (GELA) Study LNH03-2B. Blood 2010;116:abstract 109.
21. Pfreundschuh M, Ho AD, Cavallin-Stahl E et al. Prognostic significance of maximum tumor (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: An exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008;9:435-444.
22. Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with highdose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287-1295.
23. Fietz T, Knauf WU, Hänel M, et al. Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate. Ann Hematol 2009;88: 433-439.
24. Massoud M, Koscielny S, Lapusan S et al. Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy. Leuk Lymphoma 2008; 49:1510-1515.
25. Pfreundschuh M, Trümper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-633.
26. Pangalis GA, Vassilakopoulos TP, Michalis E et al. A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44: 635-644.
27. Björkholm M, Andersson T, Albom A et al. CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (metaanalysis). Eur J Haematol 2008;80:477-482.
28. Delarue R, Tilly H, Salles G et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: Results of the interim analysis of the LNH03-6B GELA study. Blood 2009;114:abstract 406.
29. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7: 1630-1636.
30. Hodgson DC, Gospodarowicz MK. Clinical evaluation and staging of Hodgkin lymphoma. In: Hoppe RT, Mauch PT, Armitage JO et al., eds. Hodgkin Lymphoma, Second Edition. Philadelphia: Lippincott Williams & Wilkins, 2007:123-132.
31. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
32. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
33. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-578.
34. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
35. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
36. Cox DR. Regression models and life tables. J Royal Stat Soc 1972;34:187-220.
37. Novoselac AV, Kunamneni RK, McMasters M et al. Primary mediastinal large B-cell lymphoma: A retrospective study of rituximab and CHOP chemotherapy. Community Oncol 2007;4:673-677.
38. Vassilakopoulos TP, Angelopoulou MK, Galani Z et al. Primary mediastinal (thymic) large B-cell lymphoma (PMLBCL): Excellent outcome with the combination of rituximab-CHOP (RCHOP) and radiotherapy (RT). Haematologica 2005;90(suppl 2):103.
39. Ahn HK, Kim SJ, Yun J et al. Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. Int J Hematol 2010;91:456-463.
40. Trneny M, Rieger M, Osterborg A et al. The addition of rituximab eliminates the negative prognostic impact of PMBCL compared to DLBCL in young patients with CD20-positive aggressive lymphomas receiving a CHOP-like chemotherapy: Results of a subgroup analysis of the MabThera International Trial Group (MInT) study. Blood 2008;112:abstract 839.
41. Rieger M, Osterborg A, Pettengell R et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the MabThera International Trial Group study. Ann Oncol 2011;22:664-670.
42. Avilés A, Garcia EL, Fernàndez R et al. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: Conventional versus escalated chemotherapy. Ann Hematol 2002;81:368-373.
43. Zinzani PL, Stefoni V, Finolezzi E et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: A retrospective study. Clin Lymphoma Myeloma 2009;9:381-385.
44. Avigdor A, Sirotkin T, Shemtov N et al. Combination of rituximab with initial chemotherapy improves outcome of primary mediastinal B-cell lymphoma: A retrospective analysis of a single institution cohort. Blood 2007;110:abstract 1283.
45. Moskowitz CH, Schöder H, Teruya-Feldstein J et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010;28:1896-1903.
46. Moskowitz C, Hamlin PA, Maragulia J et al. Sequential dose-denseRCHOPfollowed by ICE consolidation (MSKCC protocol 01-142) without radiotherapy for patients with primary mediastinal large B-cell lymphoma. Blood 2010;116:abstract 420.
47. Schneider T, Molnar Z, Toth E et al. Excellent results in the treatment of primary mediastinal lymphomas. Blood 2010;116:abstract 4915.
48. Dunleavy K, Pittaluga S, Janik J et al. Primary mediastinal large B-cell lymphoma (PMBL) outcome is significantly improved by the addition of rituximab to dose adjusted (DA)-EPOCH and overcomes the need for radiation. Blood 2005;106:abstract 929.
49. Dunleavy K, Pittaluga S, Janik J et al. The addition of rituximab to dose adjusted (DA)-EPOCH obviates the need for radiation in the treatment of primary mediastinal large B-cell lymphoma (PMBL): A prospective study of 58 patients. Ann Oncol 2008;19(suppl 4):abstract 043.